文献速递肿瘤 PET/CT放射性药物与辐射防护

[18F]FDG PET/CT信号与接受肺活检的纤维性间质性肺病患者新血管生成标志物相关:对PET/CT在弥漫性肺疾病中应用的启示

[18F]FDG PET/CT Signal Correlates with Neoangiogenesis Markers in Patients with Fibrotic Interstitial Lung Disease Who Underwent Lung Biopsy: Implication for the Use of PET/CT in Diffuse Lung Diseases.
PubMed 文献 · J Nucl Med · 2024-04-01

研究纳入18例等待肺活检的纤维性间质性肺病(fILD)患者,行[18F]FDG PET/CT并计算靶本比(TBR),对肺活检组织免疫染色检测巨噬细胞、微血管密度(MVD)和葡萄糖转运蛋白1。结果显示仅CD105 MVD与[18F]FDG TBR呈显著正相关(Spearman秩相关0.556,P<0.05,n=13),UIP组CD105高于非UIP组(P=0.011),CD105或CD31评估的MVD可预测总生存。

要点

  • CD105 MVD与[18F]FDG TBR呈显著正相关(Spearman秩相关0.556,P<0.05,n=13)。
  • UIP组CD105 MVD高于非UIP组,差异有统计学意义(P=0.011)。
  • CD105 MVD<12 Va%/hpf或CD31 MVD<35 Va%/hpf者预后显著更好。

核心结论

  • 研究突显血管生成与[18F]FDG TBR之间的相关性。
  • MVD在UIP中高于非UIP,且与fILD患者死亡相关。
  • 这些数据为研究血管结构和血管生成在纤维化中的潜在作用奠定基础。

研究设计与样本

  • 招募18例等待肺活检的纤维性间质性肺病(fILD)患者行[18F]FDG PET/CT。
  • 以SUVmax除以肺背景SUVmin得出靶本比(TBR)。
  • 对连续石蜡包埋肺活检切片免疫染色检测CD68、CD31、CD105/内皮糖蛋白和葡萄糖转运蛋白1。
  • MVD以每个高倍视野血管面积百分比(Va%/hpf)表示。
  • 采用非参数Mann-Whitney检验比较组织学UIP与非UIP之间影像和血管生成标志物差异。

主要发现

  • 18例患者平均随访41.36个月(范围5.69-132.46个月;中位30.07个月)。
  • 仅CD105 MVD与[18F]FDG TBR呈显著正相关(Spearman秩相关0.556;P<0.05,n=13)。
  • [18F]FDG摄取与巨噬细胞葡萄糖转运蛋白1表达无相关性。
  • CD105和CD31在UIP中高于非UIP,其中CD105达到统计学显著性(P=0.011)。
  • 所有患者中,活检CD105或CD31定量的MVD可预测总生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The use of [18F]FDG PET/CT as a biomarker in diffuse lung diseases is increasingly recognized. We investigated the correlation between [18F]FDG uptake with histologic markers on lung biopsy of patients with fibrotic interstitial lung disease (fILD). Methods: We recruited 18 patients with fILD awaiting lung biopsy for [18F]FDG PET/CT. We derived a target-to-background ratio (TBR) of maximum pulmonary uptake of [18F]FDG (SUVmax) divided by the lung background (SUVmin). Consecutive paraffin-embedded lung biopsy sections were immunostained for alveolar and interstitial macrophages (CD68), microvessel density (MVD) (CD31 and CD105/endoglin), and glucose transporter 1. MVD was expressed as vessel area percentage per high-power field (Va%/hpf). Differences in imaging and angiogenesis markers between histologic usual interstitial pneumonia (UIP) and non-UIP were assessed using a nonparametric Mann-Whitney test. Correlation of imaging with angiogenesis markers was assessed using the nonparametric Spearman rank correlation. Univariate Kaplan-Meier survival analysis assessed the difference in the survival curves for each of the angiogenesis markers (separated by their respective optimal cutoff) using the log-rank test. Statistical analysis was performed using SPSS. Results: In total, 18 patients were followed for an average of 41.36 mo (range, 5.69-132.46 mo; median, 30.07 mo). Only CD105 MVD showed a significantly positive correlation with [18F]FDG TBR (Spearman rank correlation, 0.556; P < 0.05, n = 13). There was no correlation between [18F]FDG uptake and macrophage expression of glucose transporter 1. CD105 and CD31 were higher for UIP than for non-UIP, with CD105 reaching statistical significance (P = 0.011). In all patients, MVD assessed with either CD105 or CD31 quantification on biopsy predicted overall survival. Patients with CD105 MVD of less than 12 Va%/hpf or CD31 MVD of less than 35 Va%/hpf had a significantly better prognosis (no deaths during follow-up in the case of CD105) than did patients with higher scores of CD105 MVD (median survival, 35 mo; P = 0.041, n = 13) or CD31 MVD (median survival, 28 mo; P = 0.014, n = 13). Conclusion: Previous work has used [18F]FDG uptake in PET/CT as a biomarker in fILD. Here, we highlight a correlation between angiogenesis and [18F]FDG TBR. We show that MVD is higher for UIP than for non-UIP and is associated with mortality in patients with fILD. These data set the scene to investigate the potential role of vasculature and angiogenesis in fibrosis.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Porter JC, Ganeshan B, Win T, et al. [18F]FDG PET/CT Signal Correlates with Neoangiogenesis Markers in Patients with Fibrotic Interstitial Lung Disease Who Underwent Lung Biopsy: Implication for the Use of PET/CT in Diffuse Lung Diseases. J Nucl Med. 2024. PMID: 38485275. doi:10.2967/jnumed.123.266445

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。